Neurocrine Biosciences (NASDAQ:NBIX) Stock Gets Price Target Boost from Royal Bank Of Canada

Neurocrine Biosciences (NASDAQ:NBIX) had its price target boosted by investment analysts at Royal Bank Of Canada from $187.00 to $190.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price objective points to a potential upside of 14.67% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Wedbush raised their target price on Neurocrine Biosciences from $185.00 to $194.00 and gave the company an “outperform” rating in a report on Monday, August 3rd. Citigroup boosted their price target on Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Truist Financial raised their price objective on Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Cantor Fitzgerald lifted their target price on Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Wall Street Zen downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $201.45.

Neurocrine Biosciences Trading Up 14.0%

NBIX stock traded up $20.34 during mid-day trading on Tuesday, hitting $165.69. The stock had a trading volume of 749,745 shares, compared to its average volume of 1,215,711. Neurocrine Biosciences has a 52 week low of $122.14 and a 52 week high of $186.12. The firm has a market capitalization of $16.84 billion, a P/E ratio of 24.31, a P/E/G ratio of 0.64 and a beta of 0.36. The firm has a fifty day simple moving average of $146.49 and a 200 day simple moving average of $147.45.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The firm’s quarterly revenue was up 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.04 EPS. As a group, equities analysts expect that Neurocrine Biosciences will post 7.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Matt Abernethy sold 2,311 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the sale, the chief financial officer owned 42,808 shares of the company’s stock, valued at $6,729,417.60. This trade represents a 5.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David Boyer sold 826 shares of the firm’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.45, for a total value of $130,053.70. Following the sale, the insider directly owned 8,722 shares in the company, valued at approximately $1,373,278.90. This trade represents a 8.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Neurocrine Biosciences during the second quarter worth about $2,310,886,000. Renaissance Technologies LLC increased its stake in shares of Neurocrine Biosciences by 8.0% in the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after buying an additional 180,100 shares during the period. First Trust Advisors LP raised its holdings in Neurocrine Biosciences by 97.0% in the 1st quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after buying an additional 472,408 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Neurocrine Biosciences in the 2nd quarter valued at approximately $117,827,000. Finally, Ieq Capital LLC bought a new position in Neurocrine Biosciences in the 2nd quarter valued at approximately $107,914,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong third-quarter performance: Neurocrine reported adjusted earnings of $3.29 per share, well above estimates ranging from $1.91 to $2.67 and up from $2.04 a year earlier. Revenue rose 41.3% year over year to $1.12 billion, exceeding the approximately $1.04 billion consensus. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Product sales surpassed $1 billion: Management said quarterly net product sales exceeded $1 billion for the first time, reflecting strong demand across its portfolio. The company also raised 2026 net sales guidance for INGREZZA to $2.9 billion-$2.925 billion, reinforcing expectations for continued commercial momentum. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: Analysts raised targets: Canaccord Genuity increased its target from $210 to $220 and assigned a “buy” rating, while Piper Sandler raised its target from $210 to $215 and maintained an “overweight” rating. Both targets imply substantial appreciation from the referenced $145.35 share price. Canaccord Genuity Group Recommendations Piper Sandler Recommendations
• Neutral Sentiment: Investor focus is likely to remain on management’s earnings-call commentary regarding demand trends, guidance and the company’s broader product pipeline. No material negative development was reported in the supplied coverage. Neurocrine Q3 2026 Earnings Call Transcript

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.